BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. According to the report, BiondVax reported that in a continuation of the study, COVID-19 illness was virtually prevented in hamsters that received BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2. The report noted that data gathered from the preclinical trial show that BiondVax’s NanoAb has potential to serve as both a therapeutic and protective prophylactic drug, which further enhances its value proposition. This data becomes even more notable because studies show that individuals participating in the COVID vaccine is declining and the effectiveness of the vaccine diminishes over a short period of time. The anti-COVID NanoAb is inhaled, making it easy and convenient to self-administer; data gathered so far indicates that the treatment is safe and well tolerated; the company still needs to perform toxicity and safety studies before human clinical trials can be conducted. “Our previous price target of $7 did not reflect the recent revaluation of the company’s American Depository Shares,” the Aegis Capital Corp. report states. “Since there are now 10x less ADS outstanding, our price target is accordingly raised to $70.”
To request access to the full report, visit https://ibn.fm/mD1Dv
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.